Stock ACHILLION PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Insiders Achillion Pharmaceuticals, Inc.

Equities

US00448Q2012

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Achillion Pharmaceuticals, Inc. Announces Management Changes
CI
Achillion Pharmaceuticals, Inc. Announces Management Changes, Effective as of February 11, 2019
CI
Achillion Pharmaceuticals, Inc. Elects Nicole Vitullo to Chair the Board of Directors
CI
Achillion Pharmaceuticals, Inc. Announces Executive Changes
CI
Achillion Pharmaceuticals, Inc. Announces Resignation of Mary Kay Fenton as Executive Vice President, Effective on December 28, 2018
CI
Achillion Pharmaceuticals, Inc. Appoints Paul Firuta to the Position of Executive Vice President and Chief Operating Officer
CI
Achillion Pharmaceuticals, Inc. Announces Executive Appointments
CI
Achillion Pharmaceuticals, Inc. Announces Executive Appointments
CI
Achillion Pharmaceuticals, Inc. Announces Management Changes
CI
Achillion Pharmaceuticals, Inc. to Reduce Workforce by Approximately 20% to Approximately 70 Employees; Promotes Joseph Truitt to President and Chief Operating Officer
CI
David Apelian Delivers Resignation as Executive Vice President, Chief Medical Officer of Achillion Pharmaceuticals, Inc., Effective December 28, 2017
CI
Achillion Pharmaceuticals, Inc. Announces Board Appointments
CI
Achillion Pharmaceuticals, Inc. Announces Executive Changes
CI
Achillion Pharmaceuticals, Inc. Announces Board Changes
CI
Achillion Pharmaceuticals, Inc. Announces Management Changes
CI
Achillion Pharmaceuticals, Inc. Names Joel Barrish as Chief Scientific Officer and Executive Vice President
CI
Achillion Pharmaceuticals Appoints Frank Verwiel to its Board of Directors
CI
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
GL
Achillion Pharmaceuticals, Inc. Announces Resignation of Dennis Liotta as Class I Director
CI
Achillion Pharmaceuticals, Inc.’s Executive Vice President and Chief Regulatory Officer Gautam Shah to Departure from the Company Effective March 31, 2015
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Achillion Pharmaceuticals, Inc.
  5. Insiders